Sanofi's Toujeo® Demonstrated a Consistently Lower Rate of Hypoglycemia Compared to Lantus® at All Levels of HbA1c control
Paris (ots/PRNewswire) - - Benefits on adherence and HbA1c to be validated in a real-world setting - Sanofi (http://www.sanofi.com) announced today that adults with type 2 diabetes treated with Toujeo® (insulin glargine 300 Units/mL) experienced a consistently lower rate of confirmed or severe hypoglycemia both at ...